Long- term outcome of thalidomide and cyclosporine in patients with IPSS low/intermediate- 1 myelodysplastic syndromes.
- Author:
Jingya WANG
1
;
Tiejun QIN
1
;
Zefeng XU
1
;
Yue ZHANG
1
;
Hongli ZHANG
1
;
Liwei FANG
1
;
Lijuan PAN
1
;
Naibo HU
1
;
Shiqiang QU
1
;
Bing LI
1
;
Zhijian XIAO
1
Author Information
- Publication Type:Journal Article
- MeSH: Anemia; Blood Platelets; Blood Transfusion; Bone Marrow; China; Cyclosporine; therapeutic use; Erythrocytes; Humans; Myelodysplastic Syndromes; classification; drug therapy; Neutrophils; Peptide Hydrolases; metabolism; Remission Induction; Retrospective Studies; Thalidomide; therapeutic use; Treatment Outcome
- From: Chinese Journal of Hematology 2015;36(11):942-946
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the long- term outcome of cyclosporin A (CsA) combined with thalidomide regime for Chinese patients with IPSS low/intermediate- 1 myelodysplastic syndromes (MDS) without del(5q)and the predictive variables which could impact the response to the therapy.
METHODSSeventy-six MDS patients who were treated with these drugs at a single institute in China were retrospectively analyzed. The polymorphism of cereblon gene, rs1672753, was detected in patients of this cohort by PCR and direct sequencing.
RESULTSA total of 53% of patients showed hematological improvement(HI)to the therapy. Thirty-one patients(31/73, 43%)achieved erythrocyte response(HI-E); 15 patients(15/50, 30%)achieved neutrophil response(HI-N); 18 patients(18/58, 31%)achieved platelet response(HI-P). Twenty-seven of the 50 patients(46%)who were dependent on red blood cell transfusion achieved HI- E and became independent of transfusion. The median duration of response among the responders was 22 months (range, 1- 131 + months). Bone marrow blasts ≤2% was the only factor associated with longer response duration in univariate analysis (P=0.010). There was no significant difference between the two groups of celeblon gene rs1672753 polymorphism either on the response rate or the response duration. The median survival of 67 patients without stem cell transplantation was 82 months. In multivariate analyses, factors significantly correlated with survival were IPSS-R(HR=3.461, 95%CI 1.126-10.639, P=0.030), age ≥ 60 y(HR=4.120, 95%CI 1.070-15.867, P=0.040)and HI-N(HR=7.733, 95%CI 1.007-59.396, P=0.049).
CONCLUSIONCsA combined with thalidomide regime could improve the anemia symptom in low/int-1 risk MDS patients without del(5q). The predictive value of cereblon gene polymorphism, rs1672753, could not be verified in this study.